Steritas LLC., a company dedicated to enhancing care for steroid-treated patients, today announced a licensing agreement with argenx, a global immunology company, for use of its STOX® Suite of steroid ...
Discover a trial that included 135 adults, randomly assigned to receive either inebilizumab or a placebo for a 52-week ...
Sivakumar VijayaraghavaluThe formative years of childhood, especially from birth to age five, lay the foundation for lifelong health and well-being. Unfortunately, when young children are subjected to ...
CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases ...
3 Centre de Recherche en Epidémiologie et Statistiques (CRESS), Unité Inserm 1153, Université Paris Cité, Paris, France ...
For patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the ...
Upadacitinib 15 mg plus a 26-week GC taper outperformed placebo in combination with a 52-week GC taper for the treatment of ...
No significant difference found between hydrocortisone replacement and prednisone tapering for glucocorticoid discontinuation ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
In mice, stress altered the way that the brain packaged memories, resulting in an unnecessary fear response — but drugs were ...
Variants of the PER3 gene disrupt adrenal adaptation to winter light, leading to serotonin disruption and depression-like ...
Castillo-Ramírez, LA, Ryu, S and De Marco, RJ (2024) Cortisol dynamics and GR-dependent feedback regulation in zebrafish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback